

1 **TITTLE**

2 The relationship of psychological factors and asthma control to health-related quality of
3 life

4

5 **Authors**

6 González-Freire, Beatriz^a PhD; Vázquez, Isabel^b PhD; Sonia Pértega-Díaz^c PhD

7 ^a Beatriz Gónzalez-Freire

8 Private Psychological Practice Beatriz González Freire. Ourense. Spain

9 ^b Isabel Vázquez

10 Department of Clinical Psychology and Psychobiology. University of Santiago de
11 Compostela. Santiago de Compostela. Spain

12 ^c Sonia Pértega-Díaz

13 Clinical Epidemiology and Statistics Unit, Complejo Hospitalario Universitario. A
14 Coruña. Spain.

15

16

17 **Corresponding author:**

18 M^a Isabel Vázquez Rodríguez

19 *Departamento de Psicología Clínica y Psicobiología. Facultad de Psicología. Universidad de Santiago*
20 *de Compostela, Santiago de Compostela*

21 *15782 Santiago de Compostela. Spain.*

22 *Telephone: 34981563100 ext.13731*

23 *e- mail: mariaisabel.vazquez@usc.es*

24

25 Abstract: 232 words

26 Text: 3500

27 **ABSTRACT**

28 **BACKGROUND:** Psychological variables (anxiety, depression and coping strategies)
29 and asthma control (assessed from the patient's perspective or from the physician's
30 perspective) affect health-related quality of life (HRQoL) in asthmatic patients.
31 However, no study has simultaneously evaluated these variables to understand the
32 independent contribution of each one of these factors on HRQoL.

33 **OBJECTIVE:** To determine the impact of anxiety, depression, coping strategies and
34 asthma control on HRQoL, and to compare the impact of asthma control on HRQoL
35 when it is established by the physician versus when it is considered by the patient.

36 **METHODS:** 373 asthmatics completed the Hospital Anxiety and Depression Scale,
37 Coping Orientations to Problems Experienced Inventory, 36-Item Short-Form Health
38 Survey (SF-36) and St George Respiratory Questionnaire (SGRQ). Asthma control was
39 measured by the patient with Asthma Control Test and by the physician with the
40 classification asthma control of Global Initiative for Asthma. Demographic and clinical
41 characteristics were also collected.

42 **RESULTS:** Anxiety, depression and poor patient-rated asthma control status were
43 associated with worse HRQoL in all dimensions (except Mental Health for asthma
44 control). Physician-rated asthma control was related to worse HRQoL in physical
45 generic and specific dimensions. Among coping strategies, only avoidant coping
46 impacted HRQoL in a few dimensions.

47 **CONCLUSIONS:** Anxiety, depression and asthma control (specially patient-rated
48 asthma control) were important independent predictors of asthma HRQoL, and all of
49 them should therefore be considered in interventions to improve HRQoL in asthmatic
50 patients.

51 **HIGHLIGHTS BOX**

52 ***What is already known about this topic?*** Anxiety, depression, avoidant coping and
53 asthma control (estimated by the patient or by the physician) affect quality of life;
54 however, these factors have not been concurrently evaluated to determine their
55 independent contribution to asthma quality of life.

56

57 ***What does this study add to our knowledge?*** Anxiety, depression and patient-rated
58 asthma control are important independent contributors to asthma quality of life and they
59 are associated almost all dimensions. The impact of physician-rated control and
60 avoidant coping on quality of life is lower.

61

62 ***How does this study impact current management guidelines?*** Anxiety, depression and
63 control of asthma (preferably estimated by the patient) should be routinely screened in
64 asthmatic patients, and interventions focused on these potentially modifiable factors
65 should be implemented to improve quality of life in asthmatic patients.

66

67 **Keywords:**

68

69 *Asthma; Asthma control; Health-related quality of life; Anxiety; Coping strategies;*70 *Depression.*

71

72 ***Conflict o interest***

73 Beatriz González Freire has received research support from the María Barbeito

74 Programme of the Consellería de Innovación e Industria de la Xunta de Galicia. The rest

75 of the authors declare that they have no relevant conflicts of interest

76 **ABBREVIATIONS USED**

77

78 ACT: Asthma Control Test

79 B: non-standardized regression coefficient

80 BMI: Body mass Index

81 CI: Confidence Interval

82 COPE: Coping Orientations to Problems Experienced Inventory

83 GINA: Global Initiative for Asthma

84 HADS: Hospital Anxiety and Depression Scale

85 HADS-A: Hospital Anxiety and Depression Scale – Anxiety Subscale

86 HADS-D: Hospital Anxiety and Depression Scale –Depression Subscale

87 HRQoL: Health-related quality of life

88 M: Mean

89 Max: Maximum

90 Mdn: Median

91 Min: Minimum

92 N: Total sample size

93 R²: Coefficient of determination

94 SD: Standard deviation

95 SF-36: 36-Item Short-Form Health Survey

96 SGRQ: St. George's Respiratory Questionnaire

97 % FEV₁: percentage of predicted value of forced expiratory volume in 1 second

98

99

100

101

102

103

104 **Introduction**

105 Asthma can affect health-related quality of life (HRQoL), but the degree to which this
106 chronic disease influences HRQoL depends on multiple factors.

107 Most of the investigations have focused on the role played by sociodemographic,
108 lifestyle or clinical variables on HRQoL [1-8], but the influence of psychological
109 variables have received less attention. Among psychological variables, anxiety and
110 depression are the most frequently evaluated (because comorbidity is common in
111 patients with asthma [9-13]), whereas the coping strategies used by the patient to deal
112 with the disease have been evaluated in a smaller number of studies [14].

113 Anxiety, depression and coping strategies are associated with HRQoL independent of
114 other potentially confounding variables such as sociodemographic, lifestyle, and clinical
115 variables [15-22], but only a few studies have evaluated the role of some of these
116 psychological variables (anxiety or depression but not coping) on HRQoL also
117 considering the effect of asthma control and their results are inconclusive [23-26].
118 Considering at the same time the effect of these three psychological variables and
119 asthma control is important because poor asthma control has been associated with
120 higher anxiety and depression [21,27-29] and a higher use of avoidant coping strategies
121 [30], and poor asthma control has also been closely associated with worse HRQoL [31-
122 34]. Hence, is still necessary to better understand the interplay and the unique
123 contribution of each one of these factors on HRQoL. However, to the best of our
124 knowledge, no study has simultaneously evaluated the effect of anxiety, depression and
125 coping strategies and of asthma control on HRQoL.

126 In addition, there is a no gold standard measure for asthma control, so that usually two
127 types of approaches are employed: from the patient's perspective, using validated self-

128 report measures, or from the physician's perspective, according to clinical and
129 pulmonary function parameters. Both types of control measures provide only fair to
130 moderate agreement [35], and so far, whether there is a differential impact of asthma
131 control on HRQoL as a function of the type of assessment used has not been evaluated.

132 The aim of this study was to determine the impact of anxiety, depression, coping
133 strategies, and asthma control on generic and specific domains of HRQoL in asthmatic
134 patients and to provide an insight of the impact of asthma control on HRQoL when
135 asthma control is established by a physician versus when control is considered by the
136 patient.

137

138

139

140

141

142

143

144

145

146

147

148

149 **Methods**

150 **Patients**

151 Using a cross-sectional study, we recruited participants consecutively from outpatients
152 of the allergy or pneumology practices of the University Hospital Complex of Ourense
153 (Spain) a tertiary center belonging to the Spanish public healthcare system that attends
154 to patients referred from primary care. Inclusion criteria were: 1) a physician's
155 diagnosis of asthma; 2) at least 6-months since the diagnosis; 3) age between 18 and
156 75 years; 4) reading-writing ability in Spanish; and 5) no diagnosis of other physical or
157 psychiatric chronic comorbid illnesses, except for rhinitis.

158 A psychologist collected the sociodemographic (sex, age, educational level,
159 employment situation, self-reported social class and marital status) and lifestyle data
160 (smoking and body mass index) in an interview. The specialized physician responsible
161 for the patient's treatment filled in a clinical data form with the following information:
162 age at asthma diagnosis, duration of disease, percentage of predicted value of forced
163 expiratory volume in 1 second (% FEV₁), asthma control level according to the Global
164 Initiative for Asthma criteria (GINA, 2006) [36] and severity of asthma according to
165 GINA (2009) criteria [37].

166 Patients also completed the following questionnaires: Hospital Anxiety and Depression
167 Scale (HADS) [38]; Coping Orientations to Problems Experienced Inventory (COPE)
168 [39]; Asthma Control Test (ACT) [40]; 36-Item Short-Form Health Survey (SF-36)
169 [41]; St. George's Respiratory Questionnaire (SGRQ) [42]. The Spanish adaptations of
170 the questionnaires were used in all cases [43-47].

171 The study was approved by the Galician Ethical Research Committee with the code
172 2009/408.

173 **Statistical Analysis**

174 For the descriptive analysis, the continuous variables are presented as mean, standard
175 deviation, and range, and the categorical variables as frequency and percentage
176 (excluding missing values) with a confidence level of 95%.

177 To quantify the impact of bronchial asthma on HRQoL we considered the scores in the
178 eight dimensions of the SF-36 expressed on a scale from 0 (maximum impairment) to
179 100 (no impairment) and the three dimensions and overall score of SGRQ in a scale
180 from 0 (minimum impairment) to 100 (maximum impairment). In addition, the scores
181 in the eight dimensions of the SF-36 questionnaire were standardized according to
182 Spanish population reference standards obtained by Alonso et al. [48]. Standardized
183 values are expressed in standard deviations from the score of the Spanish general
184 population of the same age and sex (which would receive the value of 0).

185 The degree of asthma control according to ACT criteria was divided into two
186 categories: controlled asthma ($ACT \geq 20$) vs uncontrolled asthma ($ACT < 20$). The
187 classification of control performed by the physician according to GINA criteria [36]
188 also had two categories: controlled asthma vs uncontrolled asthma (patients with
189 partially controlled asthma or uncontrolled asthma). To study the concordance between
190 two classification of asthma control (ACT and GINA criteria) Kappa index was
191 calculated.

192 When the two classifications of control were considered simultaneously, patients with
193 $ACT \geq 20$ plus controlled asthma according to GINA criteria [36] were categorized as
194 controlled asthma. All other cases were considered as uncontrolled asthma.

195 For the univariate analysis between HRQoL scores (standardized SF-36 and direct
196 SGRQ scores) and sociodemographic, clinical, and psychological variables, we applied

197 Student's *t*-test or ANOVA and the U-Mann-Whitney or Kruskal-Wallis test (as
198 appropriate after verifying the normality with the Kolmogorov-Smirnov test and the
199 number of categories of the variables analyzed) and Spearman's rho correlation
200 coefficient.

201 Using results from the univariate analysis, we developed general linear models for each
202 of the standardized dimensions of the SF-36 scores and for the SGRQ scores. When the
203 requirement of normality in HRQoL scores was not met, we used the Box-Cox family
204 of transformations. In all the analyses, sex, age, smoking, and asthma control level
205 (considering ACT criteria plus GINA criteria [36]) were included as independent
206 variables as well as all the sociodemographic, clinical, and psychological variables that
207 obtained a level of significance $<.20$ in the univariate analyses. For the inclusion of
208 anxiety and depression in these models, and due to the small number of patients
209 presenting with only depression, the participants were classified into three groups: (a)
210 no anxiety or depression (HADS-A < 8 and HADS-D < 8); (b) only anxiety (HADS-A \geq
211 8 and HADS-D < 8); and (c) suffering from depression with or without anxiety
212 (depression HADS-D ≥ 8 and HADS-A < 8 or ≥ 8). These models also considered the
213 effect of the interactions between variables.

214 With the aim of identifying which of the two classifications of asthma control
215 (estimated by the patient vs estimated by the doctor) was the best predictor of HRQoL,
216 the general linear models for each of the evaluated HRQoL dimensions were replicated,
217 considering the degree of control only via ACT criteria or only via GINA criteria [36].

218 A sample size of $n=373$ was included, which allows to estimate patients' characteristics
219 with a precision of $\pm 5.1\%$ and 95% confidence. Since asthma was evaluated with both

220 methods (ACT plus GINA criteria) in only 285 patients, percentage of patients with
221 controlled asthma could be estimated with a precision of $\pm 5.8\%$ and 95% confidence.

222 In all statistical analyses, an alpha level of .05 was established. The SPSS 19.00
223 package for Windows and the 2.12.2 version R package were used.

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241 **Results**

242 A total of 373 asthmatic patients (55.3% were recruited in allergy practices, and 44.7%
243 in pneumology practices) participated in the study. Characteristic of the sample are
244 summarized in Table 1. The mean age of this sample was 36.88 ± 14.90 years (range 18
245 – 75), the mean age of the patients when they were diagnosed with asthma was $25.62 \pm$
246 14.82 years (range 1– 67), and the mean duration of the disease was 11.98 ± 10.90 years
247 (range 0 - 67). The treatment the patients were prescribed is described in Table 1.

248

249 Regarding asthma control, the administration of the ACT questionnaire revealed that
250 57.7% of the patients had well-controlled asthma and regarding the classification of the
251 degree of control established by the physician according to GINA criteria [36] 65.6%
252 were categorized as well-controlled asthma. The Kappa index between the two methods
253 used to measure asthma control was 0.45 (95% CI 0.34-0.55). Among the 285 patients
254 in whom control of asthma was evaluated with both methods (ACT plus GINA criteria),
255 asthma was categorized as controlled in 49.1% of the patients. In these controlled
256 patients, the asthma severity classification according to GINA criteria [37] was: 51.4%
257 intermittent asthma, 7.8% mild persistent asthma, 25% moderate persistent asthma, and
258 15.7% severe persistent asthma.

259 With regard to the psychological variables, 35.4% of the patients suffered from anxiety
260 (HADS-A ≥ 8), and 14.3% of the patients presented depression (HADS-D ≥ 8). In the
261 total sample, 11% of the patients had combined anxiety and depression (HADS-A ≥ 8
262 and HADS-D ≥ 8). The most frequently used coping strategy was Behavioral Coping

263 with the problem (2.87 ± 0.44), while the least frequently used were Consumption of
264 alcohol and/or drugs (1.05 ± 0.21) (see Table 2).

265 Considering direct scores in the generic SF-36 questionnaire, the most affected
266 dimension were General Health in SF-36 (53.58 ± 21.42) and Symptoms in SGRQ
267 (40.22 ± 19.93) whereas the least affected were Social Functioning in SF-36 ($81.57 \pm$
268 24.76) and Impact in SGRQ (22.87 ± 19.39) (see Table 3).

269 Compared with the general population, using standardized scores of SF-36, the sample
270 of asthmatic patients evaluated had poorer HRQoL in all the dimensions of the SF-36,
271 and General Health (-1.03 ± 1.15) was the most affected, whereas the least affected was
272 Mental Health (-0.25 ± 1.08) (see Figure 1).

273 For each dimension of the SF-36 and the SGRQ, the sociodemographic, clinical and
274 psychological variables identified by univariate analysis were entered as candidate
275 predictors in the multivariable analysis (data not shown).

276 The results of the multivariable analyses of the SF-36 and SGRQ questionnaires are
277 shown in Tables 4 and 5, respectively. In the multivariable regression analysis, using
278 data from $n=285$ with both ACT and GINA criteria available, the only demographic
279 and lifestyle variables retained as significant predictors of poorer HRQoL were female
280 sex, younger age, non-active working situation, former smoker, and obesity ($p < .05$).

281 The interaction effect between age and sex was significant in Physical Functioning ($p =$
282 $.025$) indicating that an increase in age was associated with an increase of the Physical
283 Functioning score, and this increase was greater among females. The effect of obesity
284 on the dimension Activity and Overall score SGRQ was higher when the patient was
285 actively employed ($p < .05$). Among the clinical variables, only $FEV_1 < 80\%$ of the
286 predicted value was related to Physical Functioning and General Health of the SF-36

287 ($p < .05$) and to Activity of the SGRQ ($p = .038$). By contrast, in all the generic and
288 specific scales, anxiety and/or depression were associated with poorer HRQoL. The
289 presence of depression or depression plus anxiety was consistently associated with
290 worse HRQoL, both in the dimensions of the SF-36 questionnaire ($p < .001$) and in
291 those of the SGRQ questionnaire, as well as in its Overall score ($p < .01$). The presence
292 of only anxious symptoms was also associated with significantly worse HRQoL in all
293 the dimensions of the SF-36 ($p < .01$, with the exception of the Role Physical
294 dimension) and in all dimensions and the Overall score SGRQ ($p < .05$). There were
295 significant interactions between sex and anxiety symptoms in the Mental Health
296 dimension of the SF-36 ($p = .027$) and in the Impact dimension ($p = .028$) and the
297 Overall score SGRQ ($p = .011$). There were also significant interactions between sex
298 and depressive or anxious plus depressive symptomatology in the dimensions Activity
299 ($p = .027$) and Impact ($p = .043$) of the SGRQ. In all cases, the effect of psychological
300 comorbidity on HRQoL was slightly higher in males. Poor asthma control was also
301 closely related to HRQoL in the physical dimensions of the SF-36: Physical
302 Functioning, Role Physical, Bodily Pain, General Health, and Vitality ($p \leq .001$), as
303 well as with all domains and the Overall score SGRQ ($p < .001$). The impact of coping
304 strategies on HRQoL was more limited. A greater use of Cognitive Avoidant was
305 associated with greater deterioration in the dimensions of Social Functioning and Role
306 Emotional of the SF-36 ($p < .01$), and a greater use of Behavioral Avoidant was
307 associated with greater impact on the Symptoms dimension of the SGRQ ($p = .022$).

308 The selected characteristics explained an acceptable proportion of variability (R^2),
309 ranging from 15% in Bodily Pain to 44% in Mental Health in the dimensions of the SF-
310 36, and ranging from 28% in Symptoms to 56% in the Overall score SGRQ (see Tables
311 4 and 5). In 9 of the 12 analyzed models, the percentages of explained variance

312 exceeded 25%, generally taken as the minimum above which the model can be
313 considered acceptable [49].

314 Results of multivariable analysis of HRQoL, considering separately each of the two
315 classifications of the degree of asthma control, using n=303 patients with ACT criteria
316 (Model 1) and n=288 with GINA criteria (Model 2), respectively, showed that, the
317 percentage of explained variance of the generic and specific dimensions of HRQoL was
318 slightly higher when asthma control was considered according to ACT criteria (in the
319 SF-36, values ranging between 17% of Bodily Pain and 48% of Mental Health, and in
320 the SGRQ, between 29% of Symptoms and 53% of the Overall score SGRQ) than when
321 asthma control was considered according to GINA criteria [36] (in the SF-36, values
322 ranging between 11% of Bodily Pain and 48% of Mental Health, and in the SGRQ,
323 between 21% of Symptoms and 47% of the Overall score SGRQ). According to the
324 ACT classification, a significant effect of asthma control was found in eleven of the
325 twelve models (Physical Functioning, Role Physical, Bodily Pain, General Health,
326 Vitality, Social Functioning, and Role Emotional of the SF-36, and Overall score SGRQ
327 and by SGRQ dimensions) and only in eight (Physical Functioning, Role Physical,
328 General Health, and Vitality of the SF-36 and all dimensions and Overall score SGRQ)
329 when the classification of control was established based on GINA criteria [36] (see
330 Tables 6 and 7).

331 **Discussion**

332 Our results show that asthma affects both generic dimensions and specific dimensions
333 of HRQoL, and the main variables that determine this impact on HRQoL are anxiety,
334 depression and patient-rated asthma control.

335 The impact of asthma on HRQoL was assessed using two complementary approaches: a
336 generic questionnaire (SF-36) and a specific questionnaire (SGRQ). Both questionnaires
337 coincided in indicating the physical dimensions as the most damaged, whereas the
338 mental dimensions remain the least affected in line with previous studies [50,51].

339 The analysis of the variables that determine HRQoL revealed the significance of several
340 sociodemographic variables (sex, age, employment situation, and obesity) and the
341 pulmonary function. However, these variables have a rather limited effect, and each one
342 only affected one or a few domains. In contrast, anxiety and depression and asthma
343 control were strong predictors of generic and specific domains.

344 Anxiety and depression are the psychological disorders most frequently found in
345 asthmatic patients [9-13,52,53]. In our study, 35% of the patients had symptoms of
346 anxiety and 14% of the patients had depressive symptoms, and these figures are within
347 the prevalence range reported in other studies [10,26,54].

348 As could be expected, these psychosocial variables explained the variance in mental
349 health domains (Mental Health and Social Functioning of the SF-36 and Impact of the
350 SGRQ), but it is important to note that anxiety and depression also contributed to
351 explain the perception of physical status (Physical Functioning, Bodily Pain, and
352 Vitality of the SF-36 and Symptoms of the SGRQ) and of functional capacity (Role
353 Physical and Role Emotional of the SF-36 and Activity of the SGRQ).

354 Confirming prior literature, poor asthma control also substantially impaired HRQoL
355 [31-34]. In the present study, the determination of the degree of asthma control was
356 established by two methods: patient-rated asthma control status using the ACT and
357 physician-rated asthma control using GINA criteria [36]. The concordance between
358 ACT and GINA criteria [36] was moderate, similar to the study of Thomas et al. [35]

359 and the same as other studies [29,35] in finding that the rates of control reported by
360 asthmatic patients are lower than the rates determined by physicians.

361 Regardless of the procedure used to estimate asthma control (ACT plus GINA, only
362 ACT, or only GINA), we found that subjects with poor asthma control have
363 substantially impaired generic physical domains and disease-specific domains of the
364 HRQoL.

365 When we examined the association between control level estimated by the patient and
366 by the doctor and HRQoL separately, patient-rated asthma control is related not only to
367 generic physical dimensions but also to generic mental dimensions. A possible
368 explanation would be that, both in the ACT and the HRQoL instruments used, we are
369 collecting information from the same perspective (provided by the patient) and there
370 may be a biased symptom reporting that affects perception of HRQoL. However, to our
371 knowledge, this research is the first study that compared the impact on HRQoL of the
372 different methods used to classify the degree of asthma control, and future research is
373 necessary.

374 Regarding coping strategies, our results show that avoidance coping was related to
375 worse HRQoL, in line with previous studies in asthmatic patients [15, 18]. Studies of
376 patients with other chronic illnesses have found that avoidance coping is associated
377 with poor medication adherence and may result in poorer long-term outcomes for many
378 patients [55, 56]. However, the effect of avoidance coping is much more limited than
379 that found for the other psychological variables evaluated (anxiety and depression), and
380 its was only related to the dimensions Social Functioning and Role Emotional of the SF-
381 36 and Symptoms of the SGRQ.

382 The impact of anxiety, depression, and coping strategies on HRQoL could be attributed
383 to the relationship between these psychological variables with worse asthma control.
384 This relationship was shown in several studies [27-29,30] and it could be established
385 through several pathways including behavioral pathways (disorganized self-care and
386 poor health behaviors) or through the direct physiological effects of emotional status on
387 the autonomic nervous and immune systems, which increase asthma symptomatology
388 [57]. Poor asthma control could finally lead to deterioration of HRQoL. Our result
389 showed the effect of the evaluated psychological variables on HRQoL is present even
390 after controlling for asthma control.

391 In conclusion, our findings support to the proposal that, although they are interrelated
392 concepts, anxiety, depression, coping strategies and asthma control each contribute
393 independently to HRQoL.

394 Our study has several strengths. To our knowledge, this is the first study to indicate a
395 strong and independent association between anxiety, depression, coping strategies and
396 asthma control and HRQoL. In addition, we used two complementary approaches to
397 evaluate HRQoL: the SF-36, a generic questionnaire that allows comparing the health
398 status across different diseases and with general populations, and the SGRQ, a specific
399 questionnaire sensitives to patients' specific problematic respiratory areas. Finally, we
400 also considered two ways to assess asthma control (estimated by the physician and by
401 the patient) to determine whether there are differences between the two in terms of their
402 relationship with HRQoL.

403 It is also necessary to take into account some limitations of the study. Firstly, the sample
404 was only drawn from the tertiary asthma clinic and most of the patients present
405 intermittent asthma, which can affect the generalizability of our results. Moreover, we
406 established as exclusion criteria the presence of physical comorbidity, therefore,

407 findings may not generalize to overall population of asthmatics. However, this creates a
408 homogeneous sample in which the patients evaluated only suffered from bronchial
409 asthma, thus avoiding the possible effect of other comorbid diseases on HRQoL.
410 Finally, this study may be limited by the cross-sectional nature of the design that does
411 not allow the prediction of the direction of causality. Prospective studies are needed to
412 better delineate the relationships found between psychological variables, asthma
413 control, and HRQoL.

414 Given that the findings of this study showed that anxiety, depression, coping strategies,
415 and asthma control are variables that affect HRQoL independently, all of them should
416 be taken into account when considering HRQoL scores as an outcome measure in
417 asthma. It would be advisable to train healthcare professionals so that, when evaluating
418 asthmatic patients, they include screening for psychological variables and asthma
419 control estimated by the patient. Brief and easy to complete tools such as HADS and
420 ACT allow introducing the measurement of anxiety, depression and patient-rated
421 control in the routine clinical practice, in order to detect these characteristics in patients.
422 Effectively treating asthma symptoms improves asthma control and may reduce anxiety
423 and depression. A recent study has found that a significantly number of patients with
424 asthma improved anxiety and depression after 6 months of standardized treatment and
425 regular specialist care [58]. In cases where it is necessary, interventions specifically
426 focused on psychological factors should also be implemented in an attempt to improve
427 HRQoL in asthmatic patients.

428

429 *This study was funded by María Barbeito Programme of the Consellería de Innovación*
430 *e Industria de la Xunta de Galicia.*

431

432 *Acknowledgments* The authors thank Dr. José Manuel García Pazos, Dr. Pedro
433 *Marcos Velázquez, Dr. Carlos García de la Cuesta, Dra. María Genoveva Álvarez Eire*
434 *and Dra. Susana Varela for their support in register the clinic data of the patients. We*
435 *also thank Dr. Salvador Pita Fernández† his valuable contribution in the development*
436 *of this study.*

437

438

439

440

441

442

443

444

445

446

447

448

449 **REFERENCES**

450

- 451 1. Apter AJ, Reisine ST, Affleck G, Barrows E, ZuWallack RL. The influence of
452 demographic and socioeconomic factors on health-related quality of life in
453 asthma. *J Allergy Clin Immunol* 1999;103(1 Pt 1):72-78.doi: 10.1016/S0091-
454 6749(99)70528-2
- 455 2. Cisneros C, García-Río F, Romera D, Villasante C, Girón R, Ancochea J.
456 Bronchial reactivity indices are determinants of health-related quality of life in
457 patients with stable asthma. *Thorax* 2010;65(9):795-800.
458 doi:10.1136/thx.2010.137844
- 459 3. Ford ES, ManninoDM, Redd SC, Moriarty DG, Mokdad AH. Determinants of
460 quality of life among people with asthma: findings from the Behavioral Risk
461 Factor Surveillance System. *J Asthma* 2004;41(3):327-336doi: 10.1081/JAS-
462 120026090
- 463 4. Lavoie KL, Bacon SL, Labrecque M, Cartier A, Ditto B. Higher BMI is
464 associated with worse asthma control and quality of life but not asthma severity.
465 *Respir Med* 2006; 100(4):648-657. doi:10.1016/j.rmed.2005.08.001
- 466 5. Nishiyama O, Kato K, Kume H, Ito Y, Suzuki R, Yamaki K. Asthma health
467 status: influence of disease severity categorized by peak expiratory flow. *J*
468 *Asthma* 2003; 40(3): 281-287. doi: 10.1081/JAS-120018327
- 469 6. Shavit O, Swern A, Dong Q, Newcomb K, SazonovKocevar V, Taylor SD.
470 Impact of smoking on asthma symptoms, healthcare resource use, and quality of
471 life outcomes in adults with persistent asthma. *Qual Life Res*
472 2007;16(10):1555-1565. doi: 10.1007/s11136-007-9267-4

- 473 7. Siroux V, Boudier A, Antó JM, Cazzoletti L, Accordini S, Alonso J, et al.
474 Quality-of-life and asthma-severity in general population asthmatics: results of
475 the ECRHS II study. *Allergy* 2008; 63: 547-54. doi: 10.1111/j.1398-
476 9995.2008.01638.x
- 477 8. Wijnhoven HAH, Kriegsman DMW, Snoek FJ, Hesselink AE, de Haan M.
478 Gender differences in health-related quality of life among asthma patients. *J*
479 *Asthma* 2003;40(2):189-199.doi: 10.1081/JAS-120017990
- 480 9. Cooper CL, Parry GD, Saul C, Morice AH, Hutchcroft BJ, Moore J, et al.
481 Anxiety and panic fear in adults with asthma: prevalence in primary care. *BMC*
482 *Fam Pract* 2007; 8: 62. doi: 10.1186/1471-2296-8-62
- 483 10. Di Marco F, Santus P, Centanni S. Anxiety and depression in asthma. *Curr Opin*
484 *Pulm Med* 2011;17(1):39-44. doi:10.1097/MCP.0b013e328341005f
- 485 11. Goodwin RD, Jacobi F, Thefeld W. Mental disorders and asthma in the
486 community. *Arch Gen Psychiatry* 2003; 60, 1125-1130.
487 doi:10.1001/archpsyc.60.11.1125
- 488 12. Scott KM, Von Korff M, Ormel J, Zhang M, Bruffaerts R, Alonso J, et al.
489 Mental disorders among adults with asthma: results from the World Mental
490 Health Survey. *Gen Hosp Psychiatry* 2007; 29: 123-33. doi:
491 10.1016/j.genhosppsy.2006.12.006
- 492 13. Weiser EB. The prevalence of anxiety disorders among adults with asthma: a
493 meta-analytic review. *J Clin Psychol Med Settings* 2007; 14:297-307. doi:
494 10.1007/s10880-007-9087-2

- 495 14. Baiardini I, Sicuro F, Balbi F, Canonica GW, Braido F. Psychological aspects in
496 asthma: do psychological factors affect asthma management? *Asthma Res Pract*
497 2015; 1:7. doi:10.1186/s40733-015-0007-1
- 498 15. Adams RJ, Wilson D, Smith BJ, Ruffin RE. Impact of coping and
499 socioeconomic factors on quality of life in adults with asthma. *Respirology*
500 2004; 9: 87-95. doi: 10.1111/j.1440-1843.2003.00538.x
- 501 16. Al-kalemji A, Petersen KD, Sørensen J, Sherson D, Thilising T, Schlünssen V et
502 al. Factors influencing quality of life in asthmatics--a case-control study. *Clin*
503 *Respir J* 2013;7(3):288-296. doi:10.1111/crj.12006
- 504 17. Deshmukh VM, Toelle BG, Usherwood T, O'Grady B, Jenkins CR. The
505 association of comorbid anxiety and depression with asthma-related quality of
506 life and symptom perception in adults. *Respirology* 2008; 13 :695-702.
507 doi:10.1111/j.1440-1843.2008.01310.x
- 508 18. Hesselink AE, Penninx BW, Schlösser MA, Wijnhoven HA, van der Windt DA,
509 Kriegsman D, et al. The role of coping resources and coping style in quality of
510 life of patients with asthma or COPD. *Qual Life Res* 2004; 13: 509-18. doi:
511 10.1023/B:QURE.0000018474.14094.2f
- 512 19. Nishimura K, Hajiro T, Oga T, Tsukino M, Ikeda A. Health-related quality of
513 life in stable asthma: what are remaining quality of life problems in patients with
514 well-controlled asthma? *J Asthma* 2004;41(1):57-65.doi: 10.1081/JAS-
515 120024596

- 516 20. Ross JA, Yang Y, Song PXX, Clark NM, Baptist AP. Quality of life, health care
517 utilization, and control in older adults with asthma. *J Allergy Clin Immunol*
518 *Pract* 2013;1(2):157-162. doi:10.1016/j.jaip.2012.12.003
- 519 21. Shams MR, Bruce AC, Fitzpatrick AM. Anxiety Contributes to Poorer Asthma
520 Outcomes in Inner-City Black Adolescents. *J Allergy Clin Immunol Pract*
521 2018;6(1):227-235. doi:10.1016/j.jaip.2017.06.034
- 522 22. Sundh J, Wireklint P, Hasselgren M, et al. Health-related quality of life in
523 asthma patients - A comparison of two cohorts from 2005 and 2015. *Respir Med*
524 2017;132:154-160. doi:10.1016/j.rmed.2017.10.010
- 525 23. Böhmer MM, Brandl M, Brandstetter S, Finger T, Fischer W, Pfeifer M, et al.
526 Factors associated with generic health-related quality of life in adult asthma
527 patients in Germany: cross-sectional study. *J Asthma* 2017; 54: 325-34.doi:
528 10.1080/02770903.2016.1206563
- 529 24. Flor-Escriche X, Méndez-Gómez J, Poblet-Cortés R, Lamarca-Fornell L,
530 Álvarez-Álvarez S, Davies-Daunas SA. [Quality of life and associated factors in
531 asthma in a Primary Care Center. Application of the reduced version of the
532 Asthma Quality of Life Questionnaire]. *Semergen*. 2016; 42: 538-46. Spanish.
533 doi: 10.1016/j.semereg.2015.12.014
- 534 25. Sundbom F, Malinowski A, Lindberg E, Alving K, Janson C. Effects of poor
535 asthma control, insomnia, anxiety and depression on quality of life in young
536 asthmatics. *J Asthma* 2016; 53: 398-403. doi: 10.3109/02770903.2015.1126846

- 537 26. Urrutia I, Aguirre U, Pascual S, Esteban C, Ballaz A, Arrizubieta I, et al. (2012).
538 Impact of anxiety and depression on disease control and quality of life in asthma
539 patients. *J Asthma* 2012; 49: 201-8. doi: 10.3109/02770903.2011.654022
- 540 27. Ciprandi G, Schiavetti I, Rindone E, Ricciardolo F. The impact of anxiety and
541 depression on outpatients with asthma. *Ann Allergy Asthma Immunol.* 2015;
542 115: 408-14. doi: 10.1016/j.anai.2015.08.007
- 543 28. Coban H, Aydemir Y. The relationship between allergy and asthma control,
544 quality of life, and emotional status in patients with asthma: a cross-sectional
545 study. *Allergy Asthma Clin Immunol* 2014; 10: 67. doi: 10.1186/s13223-014-
546 0067-4
- 547 29. Di Marco F, Verga M, Santus P, Giovannelli F, Busatto P, Neri M, et al. Close
548 correlation between anxiety, depression, and asthma control. *Respir Med* 2010;
549 104:22-8. doi: 10.1016/j.rmed.2009.08.005
- 550 30. McCormick SP, Nezu CM, Nezu AM, Sherman M, Davey A, Collins BN.
551 Coping and social problem solving correlates of asthma control and quality of
552 life. *Chron Respir Dis* 2014; 11: 15-21. doi: 10.1177/1479972313516878
- 553 31. Chen H, Gould MK, Blanc PD, Miller DP, Kamath TV, Lee JH, et al. Asthma
554 control, severity, and quality of life: quantifying the effect of uncontrolled
555 disease. *J Allergy Clin Immunol.* 2007; 120: 396-402. doi:
556 10.1016/j.jaci.2007.04.040
- 557 32. Doz M, Chouaid C, Com-Ruelle L, Calvo E, Brosa M, Robert, J et al. The
558 association between asthma control, health care costs, and quality of life in

- 559 France and Spain. *BMC Pulm Med* 2013, 13, 15. doi: 10.1186/1471-2466-13-
560 15
- 561 33. González-Barcala FJ, de la Fuente-Cid R, Tafalla M, Nuevo J, Caamaño-Isorna
562 F. Factors associated with health-related quality of life in adults with asthma. A
563 cross-sectional study. *Multidiscip Respir Med* 2012; 7: 32. doi: 10.1186/2049-
564 6958-7-32
- 565 34. Schatz M, Mosen DM, Kosinski M, Vollmer WM, Magid DJ, O'Connor E, et al.
566 The relationship between asthma-specific quality of life and asthma control. *J*
567 *Asthma* 2007; 44: 391-5. doi: 10.1080/02770900701364296
- 568 35. Thomas M, Kay S, Pike J, Williams A, Carranza-Ronsenzweig JR, Hillyer EV,
569 et al. The Asthma Control Test™ (ACT) as a predictor of GINA guideline-
570 defined asthma control: analysis of a multinational cross-sectional survey. *Prim*
571 *Care Respir J* 2009; 18: 41-49. doi: 10.4104/pcrj.2009.00010
- 572 36. Global Initiative for Asthma. Global strategy for asthma management and
573 prevention. Revised 2006. Available from: www.ginasthma.com
- 574 37. Global Initiative for Asthma. Global strategy for asthma management and
575 prevention. Updated 2009. Available from: www.ginasthma.com
- 576 38. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta*
577 *Psychiatr Scand* 1983; 67: 361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x
- 578 39. Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: A
579 theoretically based approach. *J PersSoc Psychol* 1989; 56: 267-283. doi:
580 10.1037/0022-3514.56.2.267

- 581 40. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al.
582 Development of the Asthma Control Test: a survey for assessing asthma control.
583 J Allergy Clin Immunol 2004; 113: 59-65. doi: 10.1016/j.jaci.2003.09.008
- 584 41. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey. Manual and
585 Interpretation Guide. Boston, MA: The Health Institute, New England Medical
586 Center; 1993.
- 587 42. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure
588 of health status for chronic airflow limitation: the St. George's Respiratory
589 Questionnaire. Am Rev Respir Dis 1992;145: 1321-27. doi:
590 10.1164/ajrccm/145.6.1321
- 591 43. Caro I, Ibáñez E. La Escala Hospitalaria de Ansiedad y Depresión: su utilidad
592 práctica en Psicología de la Salud. Boletín de Psicología 1992; 36: 43-69.
- 593 44. Crespo M, Cruzado JA. La evaluación del afrontamiento: adaptación española
594 del cuestionario COPE con una muestra de estudiantes universitarios. Análisis y
595 Modificación de Conducta 1997; 23: 797-830. Spanish.
- 596 45. Vega JM, Badía X, Badiola C, López-Viña A, Olaguíbel JM, Picado C, et al.
597 Validation of the Spanish version of the Asthma Control Test. J Asthma. 2007;
598 44: 867-72. doi: 10.1080/02770900701752615
- 599 46. Alonso J, Prieto L, AntóJM. La versión española del SF-36 Health Survey
600 (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados
601 clínicos. Medicina Clínica 1995; 104: 771-76. Spanish.

- 602 47. Ferrer M, Alonso J, Prieto L, Plaza V, MonsóE, Marrades R, et al. Validity and
603 reliability of the St George's Respiratory Questionnaire after adaptation to a
604 different language and culture: The Spanish example. *Eur Respir J* 1996; 9:
605 1160-1166. doi: 10.1183/09031936.96.09061160
- 606 48. Alonso J, Regidor E, Barrio G, Prieto L, Rodríguez C, de la Fuente L. Valores
607 poblacionales de referencia de la versión española del Cuestionario de Salud SF-
608 36. *Medicina Clínica* 1998; 111: 410-16. Spanish.
- 609 49. Abraira V, Pérez de Vargas A. *Métodos multivariantes en bioestadística*.
610 Madrid: Centro de Estudios Ramón Areces; 1996. Spanish.
- 611 50. Erickson SR, Christian Jr RD, Kirking DM, Halman LJ. Relationship between
612 patient and disease characteristics, and health-related quality of life in adults
613 with asthma. *Respir Med* 2002; 96: 450-60. doi: 10.1053/rmed.2001.1274
- 614 51. Noronha-Ferreira L, Brito U, Lopes-Ferreira P. Quality of life in asthma
615 patients. *Rev Port Pneumol* 2010; 16: 23-55.
- 616 52. Afari N, Schmaling KB, Barnhart S, Buchwald D. Psychiatric comorbidity and
617 functional status in adult patients with asthma. *J Clin Psychol Med Settings*
618 2001; 8: 245-52. doi: 10.1023/A:1011912712262
- 619 53. Weatherburn CJ, Guthrie B, Mercer SW, Morales DR. Comorbidities in adults
620 with asthma: Population-based cross-sectional analysis of 1.4 million adults in
621 Scotland. *Clin Exp Allergy* 2017; 47: 1246-1252. doi: 10.1111/cea.12971
- 622 54. Steele AS, Meuret AE, Millard MW, Ritz T. Discrepancies between lung
623 function and asthma control: Asthma perception and association with

- 624 demographics and anxiety. *Allergy Asthma Proc* 2012; 33: 500-507. doi:
625 10.2500/aap.2012.33.3611
- 626 55. Albai A, Sima A, Papava I, Roman D, Andor B, Gafencu M. Association
627 between coping mechanisms and adherence to diabetes-related self-care
628 activities: a cross-sectional study. *Patient Prefer Adherence* 2017;11: 1235-1241.
629 doi:10.2147/PPA.S140146
- 630
- 631 56. Li CC, Shun SC. Understanding self care coping styles in patients with chronic
632 heart failure: A systematic review. *Eur J Cardiovasc Nurs* 2016; 15:12-19.
633 doi:10.1177/1474515115572046
- 634 57. Lavoie KL, Bacon SL, Barone S, Cartier A, Ditto B, Labrecque M. What is
635 worse for asthma control and quality of life: depressive disorders, anxiety
636 disorders, or both? *Chest* 2006; 130: 1039-47. doi: 10.1378/chest.130.4.1039
- 637 58. Sastre J, Crespo A, Fernandez-Sanchez A, Rial M, Plaza V. Anxiety,
638 Depression, and Asthma Control: Changes after standardized treatment. *J*
639 *Allergy Clinical Immunol Practice*. 2018; 6: 1953-1959.
640 doi:10.1016/j.jaip.2018.02.002

641

642 **Figure Legends**

643 *Figure 1.* Standardized scores in the eight dimensions of SF-36.

644

Table 1. Sociodemographic, life style and clinical characteristics of the sample

Characteristics	N	%	95% CI
Sex			
Female	263	70.5	[65.74, 74.72]
Male	110	29.5	[75.27, 34.25]
Education level			
Without education /primary	134	35.9	[30.92, 40.92]
Secondary	165	44.2	[39.06, 49.41]
College	74	19.8	[15.65, 24.02]
Marital status			
Single/divorced/widowed	166	44.5	[39.32, 49.68]
Married/living with a stable partner	207	55.5	[50.31, 60.67]
Employment situation			
Active	203	54.4	[49.23, 59.61]
Non-active	170	45.6	[40.38, 50.76]
Self-reported Social class			
Lower/lower-middle	78	21	[16.74, 25.30]
Middle-middle	260	70.1	[65.28, 74.87]
Upper/middle-upper	33	8.9	[5.86, 11.92]
Smoking habit			
Smoker	70	18.8	[14.67, 22.86]
Former	60	16.1	[12.22, 19.94]
Non-smoker	243	65.1	[60.17, 70.11]
BMI			
< 18.5	6	1.6	[0.20, 3.10]
18.5 – 24.99	181	49.9	[44.58, 55.14]
25 – 29.99	104	28.7	[23.86, 33.43]
≥ 30	72	19.8	[15.59, 24.07]
% FEV₁ of predicted value			
≥ 80%	265	71.4	[66.69, 76.16]
60-80%	85	22.9	[18.50, 27.32]
< 60%	21	5.6	[3.17, 8.14]
Prescribed medications			
None daily controller medication	120	32.3	[27.45, 37.24]
Low-dose ICS or LTRA	32	8.6	[5.63, 11.62]
Low-to-medium dose ICS + LABA or medium dose ICS+ theophylline/LTRA or high-dose ICS	174	46.9	[41.69, 52.11]
High-dose ICS + LABA associated or not with theophylline, LTRA, oral glucocorticosteroid or Anti-IgE	45	12.1	[8.67, 15.59]
Level of asthma control according to ACT			
Controlled asthma	175	57.7	[52.02, 63.48]
Uncontrolled asthma	128	42.2	[36.65, 47.84]
Level of asthma control according to GINA (2006)			
Controlled asthma	189	65.6	[59.96, 71.28]
Partly controlled	56	19.4	[14.70, 24.18]
Uncontrolled asthma	43	14.9	[10.64, 19.22]
Severity of asthma according to GINA (2009) in controlled patients			
Intermittent asthma	72	51.4	[42.79, 60.06]
Mild persistent asthma	11	7.8	[3.04, 12.67]
Moderate persistent asthma	35	25	[17.47, 32.53]
Severe persistent asthma	22	15.7	[9.32, 22.10]

Note: % FEV₁ = Percentage of predicted value of forced expiratory volume in 1 s; ACT = Asthma Control Test; GINA = Global Initiative for Asthma; BMI = Body mass index; ICS= inhaled corticosteroids; LABA=long-acting beta agonists; LTRA= leukotriene-receptor antagonists

Table 2. *Psychological characteristics of the sample*

Psychological variables	<i>n</i>	<i>M ± SD</i>	<i>Mdn</i>	<i>Min</i>	<i>Max</i>
HADS-A	369	6.50 ± 4.35	6	0	21
HADS-D	369	3.85 ± 3.77	3	0	19
COPE					
Behavioral coping of the problem	361	2.87 ± 0.44	2.82	1.55	4
Cognitive coping of the problem	355	2.20 ± 0.39	2.20	1	3.33
Behavioral avoidance	358	2.60 ± 0.38	2.57	1	3.86
Cognitive avoidance	359	1.64 ± 0.46	1.55	1	3.64
Emotion-focused coping	363	2.48 ± 0.57	2.42	1	4
Alcohol-drug consumption	366	1.05 ± 0.21	1	1	2.50

Note. HADS-A = Anxiety subscale of Hospital Anxiety and Depression Scale; HADS-D = Depression subscale of Hospital Anxiety and Depression Scale; COPE = Coping Orientations to Problems Experienced Inventory.

Table 3

Direct HRQOL scores in SF-36 and SGRQ

HRQOL questionnaires	<i>n</i>	<i>M ± SD</i>	<i>Mdn</i>	<i>Min</i>	<i>Max</i>
SF-36					
Physical functioning	371	80.12 ± 20.88	95	10	100
Role physical	371	75.00 ± 37.93	100	0	100
Bodily pain	369	68.73 ± 25.82	100	0	100
General health	371	53.58 ± 21.42	72	0	100
Vitality	371	60.40 ± 21.23	70	0	100
Social function	371	81.57 ± 24.76	100	0	100
Role emotional	371	72.59 ± 40.42	100	0	100
Mental health	371	68.37 ± 21.85	76	0	100
SGRQ					
Overall	367	29.67 ± 19.45	25.44	0	87.65
Symptoms	372	40.22 ± 19.93	38.89	0	90.82
Activity	370	35.86 ± 26.53	35.47	0	100
Impact	369	22.87 ± 19.39	17.85	0	90.94

Note. HRQOL = Health-related quality of life; SF-36 = 36-Item Short-Form Health Survey; SGRQ = St. George's Respiratory Questionnaire.

Table 4. Multivariable analysis of SF-36 questionnaire domains adjusting for asthma control level according to ACT criteria plus GINA (2006) criteria

SF-36	Predictors	B (95% CI)	P	R ² corrected
PhysicalFunctioning				.37
	Female sex	-91.38 (-150.94 to -31.82)	.003	
	Age	1.64 (0.37 to 2.92)	.012	
	BMI ≥ 30	-39.02 (-67.24 to -10.81)	.007	
	FEV ₁ of predicted value < 80%	-28.55(-53.20 to -3.90)	.023	
	Uncontrolled asthma	-72.65 (-95.13 to -50.17)	<.001	
	Anxiety	-37.04 (-61.34 to -12.75)	.003	
	Depression or Anxiety plus Depression	-81.94 (-112.93 to -50.96)	<.001	
	Age x Sex (female)	1.73 (0.22 to 3.24)	.025	
Role Physical				.17
	Female sex	3.94 (0.74 to 7.14)	.016	
	Uncontrolled asthma	-7.88 (-10.85 to -4.90)	<.001	
	Depression or Anxiety plus Depression	-8.84 (-13.07 to -4.61)	<.001	
BodilyPain				.15
	Uncontrolled asthma	-0.57(-0.89 to -0.24)	.001	
	Anxiety	-0.68 (-1.06 to -0.30)	<.001	
	Depression or Anxiety plus Depression	-1.03 (-1.49 to -0.58)	<.001	
General Health				.33
	Age	0.03 (0.02 to 0.04)	<.001	
	FEV ₁ of predicted value < 80%	-0.28 (-0.55 to -0.01)	.043	
	Uncontrolled asthma	-0.51 (-0.75 to -0.27)	<.001	
	Anxiety	-0.64(-0.91 to -0.38)	<.001	
	Depression or Anxiety plus Depression	-1.21 (-1.54 to -0.88)	<.001	
Vitality				.37
	Age	0.04 (0.03 to 0.06)	<.001	
	Former smoker	-0.85 (-1.60 to -0.10)	.027	
	Uncontrolled asthma	-1.08 (-1.54 to -0.63)	<.001	
	Anxiety	-1.38 (-1.90 to -0.87)	<.001	
	Depression or Anxiety plus Depression	-3.01 (-3.67 to -2.36)	<.001	
Social Functioning				.26
	Age	0.29 (0.16 to 0.41)	<.001	
	Anxiety	-12.51 (-16.91 to -8.12)	<.001	
	Depression or Anxiety plus Depression	-25.86 (-31.57 to -20.15)	<.001	
	Cognitiveavoidance	-6.87 (-11.13 to -2.61)	.002	
Role Emotional				.21
	Anxiety	-23.57 (-33.54 to -13.60)	<.001	
	Depression or Anxiety plus Depression	-40.15 (-53.06 to -27.25)	<.001	
	Cognitive avoidance	-15.48 (-24.87 to -6.09)	.001	
Mental Health				.44
	Anxiety	-3.60 (-4.50 to -2.70)	<.001	
	Depression or Anxiety plus Depression	-5.35 (-6.94 to -3.77)	<.001	
	Sex (female) x Anxiety	1.20 (0.14 to 2.25)	.027	

Table 5. Multivariable analysis of SGRQ questionnaire domains and overall score adjusting for asthma control level according to ACT criteria and GINA (2006) criteria

SGRQ	Predictors	B (95% CI)	P	R ² corrected
Overall				.56
	Female sex	1.42 (0.83 to 2.00)	<.001	
	Age	0.03 (0.02 to 0.05)	<.001	
	Employment situation (non active)	0.75 (0.28 to 1.21)	.002	
	BMI \geq 30	1.57 (0.66 to 2.49)	.001	
	Uncontrolled asthma	2.53 (2.09 to 2.98)	<.001	
	Anxiety	1.97 (1.00 to 2.94)	<.001	
	Depression or Anxiety plus Depression	2.79 (1.37 to 4.21)	<.001	
	Sex (female) x Anxiety	-1.47 (-2.59 to -0.35)	.011	
	Employment situation (non active) x BMI \geq 30	-1.43 (-2.57 to -0.30)	.014	
Symptoms				.28
	Age	0.16 (0.02 to 0.30)	.028	
	Uncontrolled asthma	16.81 (12.57 to 21.05)	<.001	
	Anxiety	4.91 (0.05 to 9.78)	.048	
	Depression or Anxiety plus Depression	8.31 (2.22 to 14.39)	.008	
	Behavioral avoidance	6.56 (0.94 to 12.18)	.022	
Activity				.47
	Female sex	4.08 (2.68 to 5.48)	<.001	
	Age	0.04 (0.00 to 0.08)	.034	
	Employment situation (non active)	2.11 (0.99 to 3.23)	<.001	
	BMI \geq 30	3.66 (1.47 to 5.85)	.001	
	FEV ₁ of predicted value < 80%	1.30 (0.07 to 2.52)	.038	
	Uncontrolled asthma	4.35 (3.25 to 5.46)	<.001	
	Anxiety	3.35 (1.01 to 5.69)	.005	
	Depression or Anxiety plus Depression	6.02 (2.61 to 9.43)	.001	
	Sex (female) x Depression or Anxiety plus Depression	-4.18 (-7.88 to -0.47)	.027	
	Employment situation (non active) x BMI \geq 30	-3.15 (-5.88 to -0.43)	.023	
Impact				.49
	Female sex	0.91 (0.39 to 1.44)	.001	
	Age	0.03 (0.02 to 0.04)	<.001	
	Employment situation (non active)	0.40 (0.02 to 0.78)	.042	
	Uncontrolled asthma	1.97 (1.57 to 2.36)	<.001	
	Anxiety	1.53 (0.67 to 2.39)	.001	
	Depression or Anxiety plus Depression	2.85 (1.56 to 4.14)	<.001	
	Sex (female) x Anxiety	-1.12 (-2.12 to -0.12)	.028	
	Sex (female) x Depression or Anxiety plus Depression	-1.44 (-2.84 to -0.04)	.043	

Table 6. Multivariable analysis of SF-36 questionnaire domains adjusting for asthma control level according to only ACT criteria (Model 1) and according to only GINA (2006) criteria (Model 2)

SF-36	Predictors	M1 asthma control according to only ACT criteria			M2 asthma control according to only GINA criteria		
		B (95% CI)	p	R ² corrected	B (95% CI)	p	R ² corrected
Physical Functioning				.37			.33
	Female sex	-91.87 (-150.93 to -32.82)	.002		-87.62 (-147.72 to -27.51)	.004	
	Age	1.69 (0.45 to 2.93)	.008		1.69 (0.41 to 2.97)	.010	
	BMI ≥ 30	-39.95 (-67.70 to -12.20)	.005		-32.91 (-61.62 to -4.20)	.025	
	FEV ₁ of predicted value < 80%	-35.94 (-59.74 to -12.13)	.003		-38.15 (-63.40 to -12.89)	.003	
	Uncontrolled asthma	-74.01 (-96.10 to -51.91)	<.001		-44.58 (-68.52 to -20.64)	<.001	
	Anxiety	-32.12 (-56.64 to -7.61)	.010		-51.11 (-75.93 to -26.29)	<.001	
	Depression or Anxiety plus Depression	-76.00 (-107.39 to 44.61)	<.001		-93.16 (-125.02 to -61.31)	<.001	
	Age x Sex (female)	1.77 (0.28 to 3.26)	.020		1.72 (0.18 to 3.25)	.028	
Role Physical				.19			.15
	Female sex	3.89 (0.78 to 6.99)	.014		4.65 (1.40 to 7.90)	.005	
	Uncontrolled asthma	-9.18 (-12.15 to -6.20)	<.001		-6.17 (-9.38 to -2.97)	<.001	
	Anxiety	---	---		-4.09 (-7.60 to -0.57)	.023	
	Depression or Anxiety plus Depression	-7.67 (-11.88 to -3.46)	<.001		-9.62 (-13.97 to -5.27)	<.001	
Bodily Pain				.17			.11
	Uncontrolled asthma	-0.76 (-1.09 to -0.43)	<.001		---	---	
	Anxiety	-0.59 (-0.97 to -0.22)	.002		-0.75 (-1.14 to -0.36)	<.001	
	Depression or Anxiety plus Depression	-0.92 (-1.38 to -0.46)	<.001		-1.20 (-1.68 to -0.73)	<.001	
General Health				.34			.32
	Age	0.03 (0.02 to 0.04)	<.001		0.03 (0.02 to 0.04)	<.001	
	FEV ₁ of predicted value < 80%	-0.33 (-0.59 to -0.07)	.013		-0.33 (-0.60 to -0.06)	.019	
	Uncontrolled asthma	-0.55 (-0.79 to -0.31)	<.001		-0.42 (-0.68 to -0.16)	.002	
	Anxiety	-0.60 (-0.86 to -0.33)	<.001		-0.73 (-1.00 to -0.46)	<.001	
	Depression or Anxiety plus Depression	-1.15 (-1.48 to -0.81)	<.001		-1.21 (-1.55 to -0.87)	<.001	
Vitality				.38			.36
	Age	0.04 (0.03 to 0.06)	<.001		0.04 (0.03 to 0.06)	<.001	
	Former smoker	-0.87 (-1.60 to -0.13)	.021		---	---	
	Uncontrolled asthma	-1.28 (-1.73 to -0.82)	<.001		-0.68 (-1.16 to -0.20)	.006	
	Anxiety	-1.23 (-1.75 to -0.72)	<.001		-1.71 (-2.24 to -1.19)	<.001	
	Depression or Anxiety plus Depression	-2.87 (-3.53 to -2.22)	<.001		-3.31 (-3.97 to -2.65)	<.001	
Social Functioning				.30			.29
	Age	0.32 (0.18 to 0.46)	<.001		0.30 (0.16 to 0.45)	<.001	
	Uncontrolled asthma	-5.10 (-9.33 to -0.87)	.018		---	---	
	Anxiety	-12.27 (-17.20 to -7.35)	<.001		-13.16 (-18.13 to -8.20)	<.001	
	Depression or Anxiety plus Depression	-25.54 (-31.83 to -19.24)	<.001		-26.99 (-33.32 to -20.66)	<.001	
	Cognitive avoidance	-5.58 (-10.35 to -0.81)	.022		---	---	
Role Emotional				.23			.22
	Duration of asthma	---	---		0.48 (0.02 to 0.94)	.043	
	Uncontrolled asthma	-9.81 (-19.57 to -0.05)	.049		---	---	
	Anxiety	-25.60 (-37.03 to -14.17)	<.001		-27.16 (-38.65 to -15.66)	<.001	
	Depression or Anxiety plus Depression	-33.75 (-48.33 to -19.18)	<.001		-37.46 (-52.07 to -22.86)	<.001	
	Cognitive avoidance	-16.14 (-26.76 to -5.51)	.003		-15.43 (-26.42 to -4.44)	.006	
Mental Health				.48			.48
	Anxiety	-3.74 (-4.73 to -2.75)	<.001		-2.92 (-3.45 to -2.38)	<.001	
	Depression or Anxiety plus Depression	-5.18 (-6.77 to -3.60)	<.001		-4.45 (-5.13 to -3.78)	<.001	
	Sex (female) x Anxiety	1.35 (0.21 to 2.50)	.021		---	---	

Table 7. Multivariable analysis of SGRQ questionnaire domains adjusting for asthma control level according to only ACT criteria (Model 1) and according to only GINA (2006) criteria (Model 2)

SGRQ	Predictors	M1 asthma control according to only ACT criteria			M2 asthma control according to only GINA criteria		
		B (95% CI)	p	R ² corrected	B (95% CI)	p	R ² corrected
Overall				.53			.47
	Female sex	1.40 (0.81 to 1.99)	<.001		1.49 (0.85 to 2.13)	<.001	
	Age	0.03 (0.02 to 0.05)	<.001		0.04 (0.02 to 0.05)	<.001	
	Non active employment situation	0.64 (0.17 to 1.12)	.009		0.72 (0.20 to 1.25)	.007	
	BMI ≥ 30	1.65 (0.73 to 2.57)	<.001		1.35 (0.37 to 2.33)	.007	
	Uncontrolled asthma	2.42 (1.96 to 2.88)	<.001		1.88 (1.36 to 2.39)	<.001	
	Anxiety	1.84 (0.84 to 2.84)	<.001		2.66 (1.59 to 3.73)	<.001	
	Depression or Anxiety plus Depression	2.84 (1.39 to 4.30)	<.001		3.71 (2.16 to 5.25)	<.001	
	Sex (female) x Anxiety	-1.46 (-2.61 to -0.31)	.013		-1.90 (-3.15 to -0.64)	.003	
	Sex (female) x Depression or Anxiety plus Depression	- - -	- - -		-2.08 (-3.78 to -0.38)	.016	
	Employment situation (non active) x BMI ≥ 30	-1.38 (-2.52 to -0.23)	.019		-1.29 (-2.53 to -0.05)	.042	
Symptoms				.29			.21
	Age	0.19 (0.05 to 0.33)	.007		0.17 (0.02 to 0.32)	.027	
	Uncontrolled asthma	17.22 (12.98 to 21.46)	<.001		13.46 (8.68 to 18.24)	<.001	
	Anxiety	- - -	- - -		6.05 (0.85 to 11.24)	.023	
	Depression or Anxiety plus Depression	7.83 (1.73 to 13.96)	.012		8.74 (2.18 to 15.30)	.009	
	Behavioral avoidance	5.85 (0.43 to 11.26)	.034		7.03 (1.10 to 12.95)	.020	
Activity				.44			.42
	Female sex	3.97 (2.57 to 5.38)	<.001		4.20 (2.75 to 5.66)	<.001	
	Age	0.04 (0.00 to 0.08)	.046		0.05 (0.01 to 0.09)	.020	
	Non active employment situation	1.98 (0.84 to 3.11)	.001		2.00 (0.82 to 3.17)	.001	
	BMI ≥ 30	3.85 (1.66 to 6.04)	.001		3.23 (1.03 to 5.44)	.004	
	FEV ₁ of predicted value < 80%	1.95 (0.74 to 3.16)	.002		1.77 (0.48 to 3.07)	.007	
	Uncontrolled asthma	3.84 (2.73 to 4.96)	<.001		3.00 (1.79 to 4.22)	<.001	
	Anxiety	3.03 (0.63 to 5.43)	.013		4.46 (2.02 to 6.90)	<.001	
	Depression or Anxiety plus Depression	6.18 (2.72 to 9.65)	.001		7.72 (4.23 to 11.22)	<.001	
	Sex (female) x Depression or Anxiety plus Depression	-4.61 (-8.38 to -0.83)	.017		-5.56 (-9.40 to -1.71)	.005	
	Employment situation (non active) x BMI ≥ 30	-3.03 (-5.76 to -0.31)	.029		-2.95 (-5.75 to -0.14)	.040	
Impact				.47			.41
	Female sex	0.97 (0.45 to 1.49)	<.001		0.96 (0.40 to 1.52)	.001	
	Age	0.03 (0.02 to 0.05)	<.001		0.03 (0.02 to 0.05)	<.001	
	Non active employment situation	- - -	- - -		0.40 (0.02 to 0.78)	.042	
	Uncontrolled asthma	1.96 (1.56 to 2.37)	<.001		1.47 (1.02 to 1.92)	<.001	
	Anxiety	1.44 (0.57 to 2.32)	.001		2.09 (1.17 to 3.02)	<.001	
	Depression or Anxiety plus Depression	2.92 (1.61 to 4.22)	<.001		3.51 (2.13 to 4.88)	<.001	
	Sex (female) x Anxiety	-1.14 (-2.14 to -0.13)	.027		-1.58 (-2.67 to -0.49)	.005	
	Sex (female) x Depression or Anxiety plus Depression	-1.65 (-3.07 to -0.24)	.022		-2.06 (-3.56 to -0.55)	.008	




Figure 1. Standardized scores in the eight dimensions of SF-36.